TABLE 2

Numbers of Patients with 18F-Fluciclovine–Avid Breast and Node Lesions and 18F-Fluciclovine Avidity Measurements

LesionNo. of patientsParameterBefore therapyAfter therapy*
Primary24Corrected SUVmax5.5 (1.4–15.5)0.1 (0.0–4.3)
Corrected SUVmax2.5 (1.1–6.0)0.1 (0.0–2.2)
MTV15.7 (3.2–63.9)1.3 (0.0–26.3)
TLA55.7 (5.0–371)1.0 (0.0–78.4)
Axillary lymph node19Corrected SUVmax4.9 (0.6–13.2)0.0 (0.0–2.6)
Corrected SUVmax2.2 (0.5–6.2)0.0 (0.0–1.3)
MTV4.1 (1.0–22.1)0.0 (0.0–11.3)
TLA10.9 (1.0–137)0.0 (0.0–15.0)
Extraaxillary lymph node3Corrected SUVmax2.0 (1.4–3.2)0.0 (0.0–0.4)
Corrected SUVmax1.2 (1.0–2.3)0.0 (0.0–0.0)
MTV1.4 (1.1–1.8)0.0 (0.0–2.5)
TLA3.2 (2.0–4.6)0.0 (0.0–2.5)

  • ↵* On scans after neoadjuvant therapy, breast lesions in 12 of 24 patients, axillary node lesions in 14 of 19 patients, and extraaxillary node lesions in 2 of 3 patients decreased to background levels. Lesions that decreased to background levels had corrected SUVmax (as well as SUVmean, MTV [in cm3], and TLA) of 0.

  • Data are reported as medians, with ranges in parentheses.